SSX3
Protein SSX3
Also known as: CT5.3, SSX3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q99909
- Gene
- SSX3
- Ensembl
- ENSG00000165584
- Chromosome
- X
- Canonical length
- 188 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli
OverviewNCBI Gene
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. While some of the related SSX genes are involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas, this gene does not appear to be involved in such translocations. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
188 residues, UniProt reviewed canonical sequence.
>Q99909|SSX3
1 MNGDDTFARR PTVGAQIPEK IQKAFDDIAK YFSKEEWEKM KVSEKIVYVY MKRKYEAMTK
61 LGFKAILPSF MRNKRVTDFQ GNDFDNDPNR GNQVQRPQMT FGRLQGIFPK IMPKKPAEEG
121 NVSKEVPEAS GPQNDGKQLC PPGKPTTSEK INMISGPKRG EHAWTHRLRE RKQLVIYEEI
181 SDPEEDDELocalizationUniProt · AlphaFold · HPA
Whether an antibody against SSX3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 12 nTPM
Expression across tissuesHPA
Tissue
- testis: 12 nTPM
- bone marrow: 0.1 nTPM
- thyroid gland: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
Single-cell type
- differentiating spermatogonia: 178 nCPM
- early primary spermatocytes: 136 nCPM
- undifferentiated spermatogonia: 18 nCPM
- late spermatids: 2.8 nCPM
- peritubular myoid cells: 0.7 nCPM
- early spermatids: 0.4 nCPM
Immune cell
- basophil: 0.2 nTPM
- eosinophil: 0.1 nTPM
- memory B-cell: 0.1 nTPM
- naive B-cell: 0.1 nTPM
- classical monocyte: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- cerebral cortex: 2.2 nTPM
- white matter: 2 nTPM
- medulla oblongata: 1.4 nTPM
- amygdala: 1.3 nTPM
- hypothalamus: 1.3 nTPM
- basal ganglia: 1.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.28
- gnomAD pLI
- 0.01
- gnomAD missense Z
- -0.48
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SSX3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SSX3 as an antibody target. Whether an autoantibody or antibody against SSX3 could matter depends on whether native SSX3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SSX3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy.
Loading the interactive Seroatlas protein explorer...